Belumosudil

Item no.	HY-15307-100mg
Manufacturer	MedChem Express
CASRN	911417-87-3
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Pancreatic Cancer Hepatic Cancer
Type	Inhibitors
Specific against	other
Purity	99.83
Citations	[1]Boerma, M., et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase. Blood Coagul Fibrinolysis. 2008 Oct;19(7):709-18.\|[2]Lee, J.H., et al. Selective ROCK2 Inhibition In Focal Cerebral Ischemia. Ann Clin Transl Neurol. 2014 Jan 1;1(1):2-14.
Smiles	O=C(NC(C)C)COC1=CC=CC(C2=NC(NC3=CC4=C(NN=C4)C=C3)=C5C=CC=CC5=N2)=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	KD025,SLx-2119
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	ROCK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	452.51
Product Description	Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties[1].
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO : 23.33 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 80°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Clinical information	Launched
Isoform	ROCK1; ROCK2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.